Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
Financials
Financial year 2025
S.C. Pharma from Dour, company number BE0700951989, closed financial year 2025 with a result of € -1,401 after tax. For that financial year S.C. Pharma recorded a gross margin of € 15,021 and equity of € 37,206. Compared with financial year 2024, the result moved from € -3,253 to € -1,401. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 17, 2026.
€ 37,206
▼ 4% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -1,401
▲ 57 % less loss than in 2024
Profit after tax over the fiscal year.
€ 3,982
▲ 35% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 31,006.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 1,002
▼ 38% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 1,748
▼ 59% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | - | € 80,854 | - | - | |
| Gross margin | € 15,291 | € 30,103 | € 12,939 | € 15,021 | ▲ 16% |
| Profit after taxes | € -3,037 | € 8,520 | € -3,253 | € -1,401 | ▲ € 1,852 |
| Equity | € 34,141 | € 41,861 | € 38,607 | € 37,206 | ▼ 4% |
| Total debts | € 60,898 | € 33,987 | € 25,117 | € 15,676 | ▼ 38% |
| Cash | - | - | € 2,954 | € 3,982 | ▲ 35% |
| Retained profit | € 27,941 | € 35,661 | € 32,407 | € 31,006 | ▼ 4% |
| Dividend | € 0 | € 800 | € 0 | € 0 | |
| Bank debt | € 17,517 | € 1,323 | € 0 | € 0 | |
| Balance sheet total | € 95,040 | € 75,848 | € 63,724 | € 52,882 | ▼ 17% |
Key figures of S.C. Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to S.C. Pharma?
What happened at S.C. Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 1,401. Source: NBB ↗
- Sabrina Curri became a director. NBB
- New establishment in Dour. KBO
- Start of the company according to the CBE. KBO
In short
From € 3,037 loss in 2022 to € 1,401 loss in 2025.
Paid € 6,112 in corporate taxes since 2022.
Best year ever: 2023, with € 8,520 profit.
Paid out € 800 in dividends to the owners in total.
Management
Behind S.C. Pharma is Sabrina Curri.
Directors
According to the 2025 annual accounts
Sabrina Curri
Director
since 2023
Establishments
Establishment units
Physical locations of this company
Rue Planche Cabeille 84
7370 Dour
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0700.951.989
- VAT number
- BE 0700.951.989
- Registered office
- Rue Planche Cabeille 84, 7370 Dour
- Names & denominations
- S.C. Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 17 August 2018
- Peppol
- Active · Active since 24 Oct 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Detailhandel in cosmetica en toiletartikelen
Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen
Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels